Skip to main content

Evaluation of the risk factors associated with high-dose chemotherapy-induced dysgeusia in patients undergoing autologous hematopoietic stem cell transplantation: possible usefulness of cryotherapy in dysgeusia prevention

Supportive Care in Cancer volume 24, pages 3979–3985 (2016)Cite this article

Abstract

Purpose

Dysgeusia is one of the sporadic adverse effects induced by chemotherapy, but it remains poorly understood. The aim of this study was to retrospectively identify the risk factors related with dysgeusia in patients undergoing autologous hematopoietic stem cell transplantation (AHSCT).

Methods

Forty-eight patients with myeloma or lymphoma undergoing AHSCT were enrolled in this study. Data regarding dysgeusia and symptoms were collected by interviews conducted by medical workers. Patient characteristics and unfavorable effects induced by dysgeusia were obtained from medical records and analyzed. Logistic regression analysis was performed to identify the risk factors related with dysgeusia.

Results

Of the 48 patients, 20 (42 %) had dysgeusia after AHSCT. The total period of parenteral nutrition (TPN) administration and period of decreased oral intake in the dysgeusia group were statistically longer than those in the non-dysgeusia group. Multivariate analyses revealed that oral mucositis (odds ratio: 30.3; p < 0.01) and the type of chemotherapy prior to AHSCT (odds ratio: 6.56; p < 0.05) were independent risk factors, while oral cryotherapy was the independent suppressive factor of dysgeusia (odds ratio: 0.14; p < 0.05).

Conclusion

Our study showed that dysgeusia after AHSCT led to the decrease in oral intake and extended the TPN administration period. Moreover, MEAM or LEED chemotherapy and oral mucositis were independent risk factors for dysgeusia in patients undergoing AHSCT, while oral cryotherapy was an independent suppressive factor for dysgeusia. Therefore, oral cryotherapy should be implemented into the regimen of supportive care management in patients undergoing AHSCT.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1

References

  1. Hovan AJ, Williams PM, Stevenson-Moore P, Wahlin YB, Ohrn KE, Elting LS, Spijkervet FK, Brennan MT, Dysgeusia Section OCSG, Multinational Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO) (2010) A systematic review of dysgeusia induced by cancer therapies. Support Care Cancer 18:1081–1087

    Article  PubMed  Google Scholar 

  2. Wickham RS, Rehwaldt M, Kefer C, Shott S, Abbas K, Glynn-Tucker E, Potter C, Blendowski C (1999) Taste changes experienced by patients receiving chemotherapy. Oncol Nurs Forum 26:697–706

    CAS  PubMed  Google Scholar 

  3. Ravasco P (2005) Aspects of taste and compliance in patients with cancer. Eur J Oncol Nurs 9(Suppl 2):S84–S91

    Article  PubMed  Google Scholar 

  4. Baharvand M, ShoalehSaadi N, Barakian R, Moghaddam EJ (2013) Taste alteration and impact on quality of life after head and neck radiotherapy. J Oral Pathol Med 42:106–112

    CAS  Article  PubMed  Google Scholar 

  5. Hong JH, Omur-Ozbek P, Stanek BT, Dietrich AM, Duncan SE, Lee YW, Lesser G (2009) Taste and odor abnormalities in cancer patients. J Support Oncol 7:58–65

    PubMed  Google Scholar 

  6. Milpied N, Deconinck E, Gaillard F, Delwail V, Foussard C, Berthou C, Gressin R, Lucas V, Colombat P, Harousseau JL, Groupe Ouest-Est des Leucémies et des Autres Maladies du Sang (2004) Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 350:1287–1295

    CAS  Article  PubMed  Google Scholar 

  7. Kröger N, Schwerdtfeger R, Kiehl M, Sayer HG, Renges H, Zabelina T, Fehse B, Tögel F, Wittkowsky G, Kuse R, Zander AR (2002) Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 100:755–760

    Article  PubMed  Google Scholar 

  8. Bellm LA, Epstein JB, Rose-Ped A, Martin P, Fuchs HJ (2000) Patient reports of complications of bone marrow transplantation. Support Care Cancer 8:33–39

    CAS  PubMed  Google Scholar 

  9. Kawabata KC, Hagiwara S, Takenouchi A, Tanimura A, Tanuma J, Tachikawa N, Miwa A, Oka S (2009) Autologous stem cell transplantation using MEAM regimen for relapsed AIDS-related lymphoma patients who received highly active anti-retroviral therapy: a report of three cases. Intern Med 48:111–114

    Article  PubMed  Google Scholar 

  10. Miyao K, Sakemura R, Imai K, Sakai T, Tsushita N, Kato T, Niimi K, Ono Y, Sawa M (2014) Upfront autologous stem-cell transplantation with melphalan, cyclophosphamide, etoposide, and dexamethasone (LEED) in patients with newly diagnosed primary central nervous system lymphoma. Int J Hematol 100:152–158

    CAS  Article  PubMed  Google Scholar 

  11. Bishton M, Gilyead M, Das Gupta E, Williams C, Russell NH, Byrne JL (2007) High dose melphalan or intermediate dose melphalan can be well tolerated and result in good response rates in selected elderly patients with myeloma. Leuk Res 31:1063–1068

    CAS  Article  PubMed  Google Scholar 

  12. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41

    CAS  Article  PubMed  Google Scholar 

  13. Mori T, Yamazaki R, Aisa Y, Nakazato T, Kudo M, Yashima T, Kondo S, Ikeda Y, Okamoto S (2006) Brief oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients. Support Care Cancer 14:392–395

    Article  PubMed  Google Scholar 

  14. Asaka S, Naitou E, Shimakawa T, Endo M, Yamaguchi K, Usuda A, Shimazaki A, Miyaki A, Murayama M, Yokomizo H, Yoshimatsu K, Shiozawa S, Katsube T, Naritaka Y (2013) Study of decreased oral intake in patients receiving neoadjuvant chemotherapy for esophageal cancer. Gan To Kagaku Ryoho 40:2103–2105

    PubMed  Google Scholar 

  15. Lilleby K, Garcia P, Gooley T, McDonnnell P, Taber R, Holmberg L, Maloney DG, Press OW, Bensinger W (2006) A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 37:1031–1035

    CAS  Article  PubMed  Google Scholar 

  16. Vokurka S, Bystricka E, Scudlova J, Mazur E, Visokaiova M, Vasilieva E, Brandejsova R, Chvojkova I, Vrabcova M, Vitkova J, Mjartanova D, Vodickova M, Bockova J, Streinerova K (2011) The risk factors for oral mucositis and the effect of cryotherapy in patients after the BEAM and HD-l-PAM 200 mg/m(2) autologous hematopoietic stem cell transplantation. Eur J Oncol Nurs 15:508–512

    Article  PubMed  Google Scholar 

  17. Aisa Y, Mori T, Kudo M, Yashima T, Kondo S, Yokoyama A, Ikeda Y, Okamoto S (2005) Oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients. Support Care Cancer 13:266–269

    Article  PubMed  Google Scholar 

  18. Najafizade N, Hemati S, Gookizade A, Berjis N, Hashemi M, Vejdani S, Ghannadi A, Shahsanaee A, Arbab N (2013) Preventive effects of zinc sulfate on taste alterations in patients under irradiation for head and neck cancers: a randomized placebo-controlled trial. J Res Med Sci 18:123–126

    PubMed  PubMed Central  Google Scholar 

  19. Halyard MY, Jatoi A, Sloan JA, Bearden JD, Vora SA, Atherton PJ, Perez EA, Soori G, Zalduendo AC, Zhu A, Stella PJ, Loprinzi CL (2007) Does zinc sulfate prevent therapy-induced taste alterations in head and neck cancer patients? Results of phase III double-blind, placebo-controlled trial from the North Central Cancer Treatment Group (N01C4). Int J Radiat Oncol Biol Phys 67:1318–1322

    CAS  Article  PubMed  Google Scholar 

  20. Suyama Y, Adachi K, Notsu Y, Satoh E, Nariai Y, Hashimoto Y, Sumi A, Kawaguchi M, Ishimura N (2009) Efficacy of corrected rapid turnover protein increment index (CRII) for early detection of improvement of nutrition status in patients with malnutrition. J Clin Biochem Nutr 45:44–48

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  21. Kubota K, Kobayashi W, Sakaki H, Nakagawa H, Kon T, Mimura M, Ito R, Furudate K, Kimura H (2015) Professional oral health care reduces oral mucositis pain in patients treated by superselective intra-arterial chemotherapy concurrent with radiotherapy for oral cancer. Support Care Cancer 23:3323–3329

    Article  PubMed  Google Scholar 

  22. McGreevy J, Orrevall Y, Belqaid K, Wismer W, Tishelman C, Bernhardson BM (2014) Characteristics of taste and smell alterations reported by patients after starting treatment for lung cancer. Support Care Cancer 22:2635–2644

    Article  PubMed  Google Scholar 

  23. Boer CC, Correa ME, Miranda EC, de Souza CA (2010) Taste disorders and oral evaluation in patients undergoing allogeneic hematopoietic SCT. Bone Marrow Transplant 45:705–711

    CAS  Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

  1. Department of Clinical Pharmacy Practice Pedagogy Institute of Biomedical Sciences, Tokushima University Graduate School, 1-78-1 Shomachi, Tokushima, 770-8505, Japan

    Naoto Okada, Shinji Abe, Chiemi Sato & Kazuyoshi Kawazoe

  2. Department of Pharmacy, Tokushima University Hospital, 2-50-1 Kuramoto, Tokushima, 770-8503, Japan

    Naoto Okada, Toshimi Nakamura, Kazuhiko Teraoka & Keisuke Ishizawa

  3. Faculty of Pharmaceutical Sciences, University of Tokushima, Shomachi-1, Tokushima, 770-8505, Japan

    Takeshi Hanafusa

  4. Department of Hematology, Endocrinology and Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School, 3-8-15 Kuramoto, Tokushima, 770-8503, Japan

    Masahiro Abe

  5. Department of Clinical Pharmacy, Institute of Biomedical Sciences, Tokushima University Graduate School, 3-8-15 Kuramoto, Tokushima, 770-8503, Japan

    Keisuke Ishizawa

Authors
  1. Naoto Okada
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takeshi Hanafusa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shinji Abe
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chiemi Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Toshimi Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kazuhiko Teraoka
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Masahiro Abe
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kazuyoshi Kawazoe
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Keisuke Ishizawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Naoto Okada.

Ethics declarations

This study was reviewed and approved by the Ethics Committee of Tokushima University Hospital.

Conflict of interest

The authors declare that they have no conflicts of interest.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Okada, N., Hanafusa, T., Abe, S. et al. Evaluation of the risk factors associated with high-dose chemotherapy-induced dysgeusia in patients undergoing autologous hematopoietic stem cell transplantation: possible usefulness of cryotherapy in dysgeusia prevention. Support Care Cancer 24, 3979–3985 (2016). https://doi.org/10.1007/s00520-016-3244-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-016-3244-9

Keywords

  • Dysgeusia
  • Oral cryotherapy
  • Autologous hematopoietic stem cell transplantation
  • Supportive care